Stocks · News reference

EXCLUSIVE: Co-Diagnostics Announces Successful Proof of Concept for Extraction-Free Ebola Test

Jul 28, 2026, 11:41 AMVandana Singh

Co-Diagnostics advances its Ebola testing capabilities, sending Bundibugyo virus test kits for evaluation and completing a new assay study.

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 13, 2026, 9:44 PMBenzinga Insights
Co-Diagnostics Reports Q2 2026 Results: Full Earnings Call Transcript
On Thursday, Co-Diagnostics (NASDAQ:CODX) discussed second-quarter financial results during its earnings call. The full transcript is provided below. Benzinga APIs provide real-time access to earnings call transcripts
Read original at benzinga
CODX
BenzingaAug 13, 2026, 8:04 PMBenzinga Newsdesk
Co-Diagnostics Q2 EPS $(1.46) Beats $(3.00) Estimate, Sales $166.131K Miss $166.500K Estimate
Co-Diagnostics (OTC:CODX) reported quarterly losses of $(1.46) per share which beat the analyst consensus estimate of $(3.00) by 51.33 percent. This is a 78.84 percent increase over losses of $(6.90) per share from the
Read original at benzinga
CODX
BenzingaAug 6, 2026, 1:31 PMBenzinga Newsdesk
Co-Diagnostics Announces FDA Submission Of Dual 510(k) With Concurrent CLIA Waiver Application For Co-Dx PCR Flu A/B & RSV Point-Of-Care Test
Read original at benzinga
CODX
SEC EDGARJul 31, 2026, 12:30 PMSEC EDGAR
8-K filing — Co-Diagnostics, Inc. (CODX)
Filed: 2026-07-31 AccNo: 0001493152-26-035553 Size: 565 KB Item 1.01: Entry into a Material Definitive Agreement Item 3.02: Unregistered Sales of Equity Securities Item 9.01: Financial Statements and Exhibits
Read original at edgar
CODX